<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We analyzed by immunocytochemistry the expression of survivin in bone marrow cells from 36 <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) cases, from 98 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and from 41 non hemopathic subjects </plain></SENT>
<SENT sid="1" pm="."><plain>Our aim was to evaluate whether abnormalites in survivin expression were associated with peculiar laboratory and clinical findings, altered <z:mpath ids='MPATH_3'>apoptosis</z:mpath> levels or altered proliferative rate </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> samples survivin was never detectable </plain></SENT>
<SENT sid="3" pm="."><plain>It was detected in almost <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with more than 5% bone marrow blasts survivin levels higher than in RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> were observed (P=0.04) </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> a tendential inverse correlation between survivin and TUNEL positivity was identified (P=0.08), whereas survivin expression was independent of the proliferative rate </plain></SENT>
<SENT sid="6" pm="."><plain>Survivin levels did not predict disease progression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients treated with intensive polichemotherapy, survivin expression was significantly higher in resistant cases (P=0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>Our findings confirm the high incidence of survivin expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Its abnormal expression also in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> may play a role in promoting aberrantly increased cell viability and contribute to the altered homeostatic balance between cell growth and cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
</text></document>